Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study
Recommended Citation
Gooderham MJ, Weidinger S, Simpson EL, Deleuran M, Stein Gold LF, Farooqui SA, Biswas P, Chan G, Güler E, Koppensteiner H. Treatment efficacy in patients with moderate-to-severe atopic dermatitis who switched from dupilumab to abrocitinib in JADE EXTEND, a phase 3 long-term extension study. Br J Dermatol 2024; 190:II32-II33.
Document Type
Conference Proceeding
Publication Date
2-7-2024
Publication Title
Br J Dermatol
Volume
190
First Page
II32
Last Page
II33
COinS
